Functional Consequences of Truncating Amino Acid Side Chains Located at a Calmodulin-Peptide Interface*

(Received for publication, October 17, 1996, and in revised form, December 19, 1996)

David Chin Dagger , David J. Sloan Dagger , Florante A. Quiocho § and Anthony R. Means Dagger

From the Dagger  Department of Pharmacology, Duke University Medical Center, Durham, North Carolina 27710 and the § Department of Biochemistry, Howard Hughes Medical Institute, Baylor College of Medicine, Houston, Texas 77030

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
FOOTNOTES
Acknowledgments
REFERENCES


ABSTRACT

To test the relevance of the calmodulin-peptide crystal structures to their respective calmodulin-enzyme interactions, amino acid side chains in calmodulin were altered at positions that interact with the calmodulin-binding peptide of smooth muscle myosin light chain kinase but not with the calmodulin kinase IIalpha peptide. Since shortening the side chains of Trp-800, Arg-812, and Leu-813 in smooth muscle myosin light chain kinase abrogated calmodulin-dependent activation (Bagchi, I. C., Huang, Q., and Means, A. R. (1992) J. Biol. Chem. 267, 3024-3029), substitutions were introduced at positions in calmodulin which contact residues corresponding to Arg-812 and Leu-813 in the smooth muscle myosin light chain kinase peptide. Assays of smooth muscle myosin light chain kinase with the calmodulin mutants M51A,V55A, L32A,M51A,V55A, and L32A,M51A,V55A,F68L, M71A exhibited 60%, 25%, and less than 1% of maximal activity respectively, whereas the mutants fully activated calmodulin kinase IIalpha . Alanine substitutions at positions on the smooth muscle myosin light chain kinase peptide, corresponding to Trp-800 and Arg-812 in the enzyme, produced an 8-fold increase in the enzyme inhibition constant in contrast with the abolition of calmodulin binding by similar mutations in the parent enzyme.


INTRODUCTION

Calmodulin (CaM)1 is an intracellular protein that binds to a wide variety of enzymes in a Ca2+-dependent manner and serves as a regulatory subunit. Three examples of such enzymes are the protein kinases smooth muscle myosin light chain kinase (smMLCK), CaM-dependent protein kinase IIalpha (CaMKIIalpha ), and skeletal muscle myosin light chain kinase (skMLCK). Since peptides derived from these enzymes can bind Ca2+/CaM with high affinity (Kd = nM), they have been treated as representative models of their respective CaM-enzyme interactions. The three-dimensional structures of the Ca2+/CaM-peptide complexes derived from these three protein kinases have been solved by x-ray crystallography or NMR spectroscopy (1-3). Although the amino acid sequence of each peptide is distinct, the three structures show similar themes. The peptides adopt a helical structure and orient antiparallel to the NH2- and COOH-terminal domains of CaM. To accommodate the different primary structures, the linker connecting the two domains of CaM serves as a variable expansion joint thus facilitating numerous van der Waals contacts between the peptides and hydrophobic pockets located in the two domains of Ca2+/CaM. On closer inspection, however, the Ca2+/CaM-peptide complexes exhibit differences in the specific details of their interactions. A comparison of the CaMKIIalpha peptide (CaMKIIalpha p)·CaM complex with the smMLCK peptide (smMLCKp)·CaM complex reveals that the NH2-terminal domain of CaM interacts differently with the COOH-terminal ends of either the CaMKIIalpha p or the smMLCKp (2). The specific contacts between the CaM domains and the peptides are important for the formation of these structures since the same contacts are maintained between the CaMKIIalpha p and CaM mutants containing multiple residue deletions and insertions in the linker between the CaM domains (4).

The relevance of the CaM-peptide structural models to the interaction between CaM and the intact enzymes remains largely untested. Previous mutagenesis studies on CaM and CaM-binding enzymes did not address this point since most failed to target the binding interface between the two proteins. One exception was an alanine scan of the CaM binding domain of smMLCK. These studies demonstrated that the side chains of Trp-800, Arg-812, and Leu-813, which interact with multiple side chains of CaM in the Ca2+/CaM·smMLCKp structure, are critical for CaM binding and activation of the enzyme (5). Collectively, the available data presented an opportunity to test whether the different CaM-peptide complexes provide information on how CaM interacts with and activates the target enzymes. To address this question two complementary approaches were taken. First, in an attempt to perturb the CaM-smMLCK interaction without interfering with the CaM·CaMKIIalpha complex we studied the effects of truncating amino acid side chains in the NH2-terminal domain of CaM which differentially interact with the smMLCKp and the CaMKIIalpha p. Consequently Ala residues were sequentially substituted for CaM residues Leu-32, Met-51, Val-55, and Met-71. These side chains interact with residues in the smMLCKp, corresponding to Arg-812 and Leu-813 in the enzyme smMLCK but have no contacts with the CaMKIIalpha p. Both enzymes were then tested for activation by the resulting double, triple, or multiple substitution mutants of CaM. Second, we tested whether simultaneous Ala substitutions of the Trp-5 and Arg-17 residues in the smMLCKp would eliminate CaM binding as was demonstrated when similar changes were made at the corresponding Trp-800 and Arg-812 in the context of the enzyme (5).


EXPERIMENTAL PROCEDURES

Site-directed Mutagenesis of CaM

Mutants of CaM were generated by the combination of two protocols. First the double mutant of CaM, M51A,V55A, was introduced into the pCaM23N plasmid containing the chicken CaM cDNA (6) by unique restriction site elimination mutagenesis (7). This procedure simultaneously eliminated the unique AccI restriction site. The protein coding region was then subcloned into the pCaMpl vector (8) via the unique 5' NcoI and 3' XbaI restriction sites to facilitate bacterial expression. The triple Ala mutant of CaM, L32A,M51A,V55A, was created by the method of site-directed polymerase chain reaction mutagenesis (9) using the pCaM23N construct containing the M51A,V55A mutant as template. The resulting NcoI-XbaI fragment was then ligated into the pCaMpl expression vector. The L32A,M51A,V55A,F68L,M71A multiple mutant of CaM was also created by polymerase chain reaction mutagenesis, but instead using the plasmid from the L32A,M51A,V55A mutant as DNA template. The identities of the mutant cDNA constructs were verified by double-stranded DNA sequencing of the entire protein coding region of CaM.

Expression and Purification of CaM

CaM mutant proteins were expressed in the heat-inducible bacterial strain N5151 and purified by conventional column chromatography as described previously (10). Briefly, bacteria were grown in 1 liter of LB broth at 30 °C to A595 = 1 and induced to express protein by heat induction at 42 °C for 1.5 h. The bacterial pellet was then collected after centrifugation, suspended in a solution of 2.4 M sucrose, and subjected to overnight lysis in a lysozyme solution. CaM was purified from the resulting lysis supernatant by phenyl-Sepharose and gel filtration chromatography. The purified proteins subsequently were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Concentrations of CaM were determined by UV absorbance (11) and by the method of Bradford (12).

CaM-binding Peptides of smMLCK

The peptides containing the sequence of the CaM binding domain of smMLCK residues 796-813 (smMLCKp) ARRKWQKTGHAVRAIGRL and the two alanine substitutions (W5A,R17A) ARRKAQKTGHAVRAIGAL were made by automated solid phase synthesis and purified by reverse phase high performance liquid chromatography. The compositions of the peptides and their respective concentrations were verified by amino acid analysis.

Assay of CaM-dependent Activation of MLC Kinase and Autophosphorylation of CaMKIIalpha

SmMLCK was purified from a baculovirus expression system and assayed for light chain phosphorylation in the presence of increasing amounts of CaM as described previously (10). Assays were initiated by the addition of enzyme (2 nM final concentration) in a total volume of 50 µl and performed for 10 min at 30 °C in 50 mM Hepes (pH 7.5), 5 mM MgCl2, 1 mM CaCl2, 1 mM dithiothreitol, 0.1% Tween 80, 0.5 mg/ml bovine serum albumin, 0.1 mM ATP (0.2 µCi), and 50 µM MLCs (17). Aliquots of 40 µl were loaded onto a Whatman 3MM filter and washed with four or five changes in a solution of 10% trichloroacetic acid and 2% sodium pyrophosphate. Assays were also conducted under similar conditions except using 200 µM of the MLC peptide MLC 11-23 as substrate. In this case aliquots were loaded onto Whatman P81 filters and washed in 75 mM phosphoric acid. Filters were counted on a Beckman LS 6000 scintillation counter. Kinetic constants for CaM and the mutant CaM were derived from the equation
<IT>v</IT><UP>=</UP><IT>V</IT><UP><SUB><IT>m</IT></SUB></UP>[<UP>Act</UP>]<UP>/</UP><IT>K</IT><SUB><UP>CaM</UP></SUB><UP>+</UP>[<UP>Act</UP>] (Eq. 1)
where v is the rate of the enzyme, [Act] is the concentration of CaM, KCaM is the concentration of CaM at half-maximal velocity, and Vm denotes the maximal enzyme velocity under conditions of saturating concentrations for both substrates and activator. All kinase assays included controls of wild type CaM at a saturating concentration of 1 µM, which was defined as 100% maximal activity.

The inhibition constant for the CaM multiple mutant L32A,M51A, V55A,F68L,M71A with smMLCK was derived from a modified version of the assay with MLC as substrate. A competition assay was performed with either 1, 2, 4 or 8 nM wild type CaM and increasing concentrations of the CaM mutant protein. Inhibition constants were derived from double-reciprocal plots and linear regression analysis. The enzyme inhibition constants for the smMLCK peptides were obtained by adding increasing concentrations (20-1000 nM) of either peptide to the smMLCK assay containing 200 nM CaM and 100 nM enzyme. Inhibition constants were derived by fitting the results from the competition assay with the CURVE-FIT program to an equation describing an activator depletion model.

Ca2+/CaM-dependent autophosphorylation of baculovirus-expressed CaMKIIalpha was measured at 1 mM CaCl2 as described (10). Kinetic constants (KCaM and percent maximum activity) were derived in a manner similar to that for smMLCK.


RESULTS AND DISCUSSION

The aim of this study was to investigate the functional implications of the CaM-peptide structures by correlating incremental structural changes at the protein-peptide interface with changes in CaM binding or enzyme activation. Therefore perturbations were introduced at the CaM·smMLCKp binding site by either by shortening side chains of CaM which exhibited differences in contacts between the smMLCKp and the CaMKIIalpha p or by shortening side chains on the smMLCKp which were required for binding and activation of the parent smMLCK enzyme.

In the first case mutations were introduced into the CaM NH2-terminal domain by combining the techniques of unique site elimination and polymerase chain reaction mutagenesis. The resulting CaM mutant constructs contained either two amino acid side chain changes, the double mutant M51A,V55A; three side chain substitutions, the triple mutant L32A,M51A, V55A; or five side chain substitutions, the multiple mutant L32A,M51A,V55A,F68L,M71A. The different CaMs were inducibly expressed in bacteria and purified using chromatographic procedures identical to those for the wild type CaM. This resulted in similar yields for all proteins of approximately 10-20 mg of protein/liter of liquid bacterial culture.

The mutant proteins were then compared with authentic CaM in their respective abilities to support autophosphorylation of the enzyme CaMKIIalpha . The resulting activation profiles at increasing concentrations of CaM are presented in Fig. 1A. Similar to authentic CaM, all mutant CaMs were capable of maximal (100%) activation of CaMKIIalpha autophosphorylation. In the specific case of the double mutant M51A,V55A, the activation constant (KCaM = 50 nM) was almost identical to that of CaM (45 nM). In contrast, the triple and multiple mutants of CaM exhibit larger increases in KCaM, which are approximately 3-8-fold greater than the normal protein, at 120 and 350 nM, respectively.


Fig. 1. Activation of CaM-dependent kinases by CaM mutant proteins. Panel A, autophosphorylation of CaM kinase IIalpha . The autophosphorylation of CaMKIIalpha was measured at increasing concentrations of CaM. Maximal activity (100%) was set at a concentration of wild type (WT) CaM of 1 µM. Panel B, activation of smMLCK. The activity of smMLCK was measured at increasing concentrations of CaM using MLCs as substrate. Maximal activity (100%) was set at that achieved by a saturating concentration of wild type CaM of 1 µM.
[View Larger Version of this Image (23K GIF file)]


The results from testing the ability of the CaM mutants to activate smMLCK phosphorylation of MLCs are plotted in Fig. 1B. In contrast to CaMKIIalpha , none of the CaM mutant protein was capable of maximally activating smMLCK. The double mutant M51A,V55A achieved 60% of the maximal activity of the wild type, whereas the triple mutant L32A,M51A,V55A resulted in only 25% of maximal activity. The multiple mutant L32A,M51A,V55A,F68L,M71A showed the largest change with less than 1% of maximal activity. Interestingly, the KCaM values for the double and triple CaM mutants were not significantly different from CaM (1.5 nM) as they increased less than 3-fold to 4.0 nM for the double mutant and 3.0 nM for the triple mutant. Since the multiple mutant L32A,M51A,V55A,F68L, M71A showed scant ability to activate smMLCK, an inhibition constant of 4.5 nM was determined from competition assays with authentic CaM. In addition, the use of the 13-residue MLC peptide MLC 11-23 as substrate in the assays gave essentially the same results as with the full-length 20-kDa light chains.

A comparison of the parameters for CaM and mutant CaM proteins is presented in Table I, listing activation constants and maximal activity for autophosphorylation of CaMKIIalpha and for phosphorylation of MLC or MLC peptide 11-23 by smMLCK. Sequential mutations of the side chains Leu-32, Met-51, Val-55, and Met-71 of CaM to Ala and Phe-68 to Leu in the NH2-terminal domain of CaM had little effect on the activation of CaMKIIalpha since the most deleterious CaM mutant, L32A,M51A,V55A,F68L,M71A, produced less than an 8-fold increase in KCaM for CaMKIIalpha while retaining 100% maximal activity. These results are consistent with the CaM·CaMKIIalpha p structural model since the truncated amino acid side chains of CaM do not interact with the CaMKIIalpha p. They also correlate closely with results from earlier studies on the NH2-terminal domain of CaM where chemical modification of Lys-75 with the phenothiazine affinity reagent norchlorpromazine isothiocyanate had little effect on the activation of CaMKII (13). In addition a chimeric protein containing the NH2-terminal domain E-F hand I of cardiac troponin C joined in-frame with the remaining portion of CaM (TaM-BM1) had at most a 5-fold increase in the activation constant for CaMKII (14).

Table I.

KCaM for enzyme activation


Calmodulin Enzyme [substrate]
CaMKIIalpha smMLCK
[LC] [LC peptide]

nM nM nM
Wild type 45 1.5 1.5
M51A,V55A 50 4.0 (60%)a 5.0 (55%)
L32A,M51A,V55A 120 3.0 (25%) 3.0 (25%)
L32A,M51A,V55A F68L,M71A 350 4.5b (<1%)    (<1%)

a  Values in parentheses are % maximum activity.
b  Inhibition constant.

In contrast with the results from CaMKIIalpha , the same CaM mutant proteins produced large reductions (>40-99%) in the maximal activity of smMLCK with little change in the activation or inhibitory constants (Table I). The mutated residues on CaM interact with a residue on the smMLCKp, corresponding to Leu-813 on the intact enzyme, which has been proposed to play an important role in the recognition of CaM (1). The small effect of these mutations on the affinity of smMLCK for CaM, as reflected in the similar activation constants (Table I), suggests that the van der Waals packing with smMLCK Leu-813 is important for activating the enzyme and less critical in the formation of a high affinity CaM·smMLCK complex. This result also agrees with those from the norchlorpromazine isothiocyanate derivative of the CaM NH2-terminal domain which was unable to activate smMLCK but still bound to the enzyme with high affinity (15). Finally, the results from a complementary study on the kinase domain of smMLCK by alanine scanning mutagenesis provide support for this point since the L813A mutant lost more than 85% of maximal activity while retaining some ability to bind CaM as assessed by a gel overlay assay (5).

It is remarkable to observe the extent to which the molecular details derived from these and other recent mutagenesis studies on the Ca2+/CaM·smMLCK interaction closely follow an earlier two-step model proposing a mechanism of CaM function based on the gross thermodynamics of the Ca2+/CaM·skMLCK interaction (17). The first event in this model involves the hydrophobic interaction between undetermined groups of the enzyme and Ca2+/CaM which function to immobilize partially both proteins while stabilizing the formation of a high affinity complex. The site of the initial, high affinity interaction between smMLCK and Ca2+/CaM has been localized to the COOH-terminal hydrophobic pocket of Ca2+/CaM by scanning mutagenesis of the nine widespread Mets of CaM (10). These experiments demonstrated that a solvent accessible hydrophobic surface in the COOH-terminal domain of Ca2+/CaM, which includes Met-109 and especially Met-124, is critical for high affinity binding with smMLCK. Importantly, this region of Ca2+/CaM has hydrophobic interactions with nonpolar residues in skMLCKp (3) and smMLCKp (1), including the equivalent of Trp-580 in skMLCK and the homologous Trp-800 in smMLCK, which is required for binding Ca2+/CaM (5).

The second step in the proposed model involves the operation of short range forces including van der Waals, hydrogen bonding, and ionic interactions that lead to enzyme activation. The results presented herein and elsewhere (10) provide compelling evidence that the disruption of van der Waals interactions between nonpolar residues of smMLCK and those in the NH2-terminal domain of CaM have dramatic effects on the maximal activity of the enzyme while scarcely affecting the affinity of the Ca2+/CaM·smMLCK complex. Other studies also suggest that van der Waals interactions between smMLCK and nonpolar residues in the COOH-terminal domain of CaM such as Met-124 and Leu-112 play a similarly important role in smMLCK activation as well (10, 18, 19). Evidence for the role of hydrogen bonding and ionic interactions comes primarily from CaM-troponin C chimeric proteins. These studies reveal that mutation of polar or charged residues located on an external "latch" surface of CaM, distinct from the CaM·smMLCKp interface, will impair activation of smMLCK but still maintain a high affinity complex (14, 16, 18, 19).

Mutagenesis studies on an enzymatically active fragment of smMLCK had shown that Trp-800 and Arg-812 were individually necessary for Ca2+/CaM-dependent binding and enzyme activation as the substitution of either residue markedly decreased both parameters (5). Since both residues interact with CaM in the Ca2+/CaM·smMLCKp complex, we prepared a peptide in which Ala substitutions were introduced simultaneously at positions corresponding to Trp-800 and Arg-812. The resulting double Ala peptide was compared with the original peptide for their respective abilities to bind to Ca2+/CaM and thus inhibit the activation of smMLCK. The two amino acid changes did not abolish the ability of the smMLCKp to bind CaM, but rather resulted in only an 8-fold diminution in the enzyme inhibition constant (Ki) from 1.3 nM to 10.4 nM (Table II).

Table II.

Inhibition constants for smMLCK peptides


nM
smMLCK-WTa 1.3
ARRKWQKTGHAVRAIGRL-Am
smMLCK-W800A,R812A 10.4
ARRKAQKTGHAVRAIGAL-Am

a  WT, wild type.

This result is consistent with those from other studies which have determined Ca2+/CaM to be capable of high affinity binding to peptides with diverse amino acid sequences (20). A major feature of peptides that bind to Ca2+/CaM is the capability to form an amphipathic helix following the binding of Ca2+/CaM. Using this premise it was possible to design a high affinity CaM-binding peptide de novo consisting only of Leu and Lys residues (LK peptide) (21). The substitution of Trp for Leu at the position of the LK peptide corresponding to Trp-5 in the smMLCKp resulted in a 10-fold increase in affinity for Ca2+/CaM (22). This result is comparable to the effect of the double Ala-substituted smMLCKp (Table II). Other studies on CaM-peptide binding demonstrate even greater plasticity on the part of the peptides. The smMLCKp composed solely of D-amino acids binds just as well to Ca2+/CaM as the peptide composed of normal L-amino acids (23). Also, a study of the skMLCKp shows that no individual Ala substitutions decreased but in all cases instead increased the affinities of the peptide for Ca2+/CaM (24).

The small effects of the double Ala substitutions on the CaM binding properties of the smMLCKp, however, do not agree with the abolition of CaM binding due to individual substitutions at the equivalent positions of Trp-800 and Lys-813 in the smMLCK enzyme. This discrepancy is an indicator of significant differences in the binding of Ca2+/CaM by nonnative peptide sequences compared with the same sequence in the context of an intact enzyme. Insight into the differences in the molecular recognition process between a free CaM-binding peptide and the same peptide segment in the environment of a folded enzyme is provided by the recently determined x-ray structure of Ca2+/CaM-dependent protein kinase I (CaMKI) (25). In this structure, the CaM binding domain of CaMKI is held in place on the surface of the kinase and makes numerous contacts with neighboring groups in both major domains of the enzyme. In one exceptional case, Trp-303 (the structural homolog to Trp-800 in smMLCK) is exposed to solvent and is thus thought to play an important role in the binding of Ca2+/CaM. In contrast to the enzyme, the free CaM-binding peptide, in the absence of constraints imposed by the remainder of the protein, would likely present a markedly different target for recognition and binding by Ca2+/CaM. However, since the peptide can form an amphipathic helix it could still bind to Ca2+/CaM with similar or even higher affinities than the parent enzyme. An intriguing question pertinent to the activation process is whether the CaM binding domain of CaMKI is transformed to a helical segment following the binding of Ca2+/CaM.


FOOTNOTES

*   This work was supported by National Institutes of Health Research Grant GM-33976 (to A. R. M.) and the Howard Hughes Medical Institute (to F. A. Q.). The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
   To whom correspondence should be addressed: Dept. of Pharmacology, Duke University Medical Center, Box 3813, Durham, NC 27710. Tel.: 919-681-6209; Fax: 919-681-7767.
1    The abbreviations used are: CaM, calmodulin; MLC, myosin light chain; smMLCK, smooth muscle myosin light chain kinase; CaMKIIalpha , Ca2+/calmodulin-dependent protein kinase IIalpha ; skMLCK, skeletal muscle myosin light chain kinase; CaMKIIalpha p, CaMKIIalpha peptide; smMLCKp, smMLCK peptide; CaMKI, Ca2+/calmodulin-dependent protein kinase I.

Acknowledgments

We thank Dr. Apolinary Sobieszek for assistance with the inhibition kinetic analyses.


REFERENCES

  1. Meador, W. E., Means, A. R., and Quiocho, F. A. (1992) Science 257, 1251-1255 [Medline] [Order article via Infotrieve]
  2. Meador, W. E., Means, A. R., and Quiocho, F. A. (1993) Science 262, 1718-1721 [Medline] [Order article via Infotrieve]
  3. Ikura, M., Clore, G. M., Gronenborn, A. M., Zhu, G., Klee, C. B., and Bax, A. (1992) Science 256, 632-638 [Medline] [Order article via Infotrieve]
  4. Meador, W. E., George, S. E., Means, A. R., and Quiocho, F. A. (1995) Nature Struct. Biol. 2, 943-945 [Medline] [Order article via Infotrieve]
  5. Bagchi, I. C., Huang, Q., and Means, A. R. (1992) J. Biol. Chem. 267, 3024-3029 [Abstract/Free Full Text]
  6. Putkey, J. A., Ono, T., VanBerkum, M. F. A., and Means, A. R. (1988) J. Biol. Chem. 263, 11242-11249 [Abstract/Free Full Text]
  7. Deng, W. P., and Nickoloff, J. A. (1992) Anal. Biochem. 200, 81-88 [Medline] [Order article via Infotrieve]
  8. VanBerkum, M. F. A., George, S. E., and Means, A. R. (1990) J. Biol. Chem. 265, 3750-3756 [Abstract/Free Full Text]
  9. Higuchi, R., Krummel, B., and Saiki, R. K. (1988) Nucleic Acids Res. 16, 7351-7367 [Abstract]
  10. Chin, D., and Means, A. R. (1996) J. Biol. Chem. 271, 30465-30471 [Abstract/Free Full Text]
  11. Klevit, R. (1983) Methods Enzymol. 102, 82-104 [Medline] [Order article via Infotrieve]
  12. Bradford, M. M. (1976) Anal. Biochem. 72, 248-254 [CrossRef][Medline] [Order article via Infotrieve]
  13. Newton, D., Klee, C., Woodgett, J., and Cohen, P. (1985) Biochim. Biophys. Acta 845, 533-539 [Medline] [Order article via Infotrieve]
  14. George, S. E., VanBerkum, M. F. A., Ono, T., Cook, R., Hanley, R. M., Putkey, J. A., and Means, A. R. (1990) J. Biol. Chem. 265, 9228-9235 [Abstract/Free Full Text]
  15. Newton, D. L., and Klee, C. B. (1984) FEBS Lett. 165, 269-272 [CrossRef][Medline] [Order article via Infotrieve]
  16. VanBerkum, M. F. A., and Means, A. R. (1991) J. Biol. Chem. 266, 21488-21495 [Abstract/Free Full Text]
  17. Blumenthal, D. K., and Stull, J. T. (1982) Biochemistry 21, 2386-2391 [Medline] [Order article via Infotrieve]
  18. George, S. E., Su, Z., Fan, D., Wang, S., and Johnson, J. D. (1996) Biochemistry 35, 8307-8313 [CrossRef][Medline] [Order article via Infotrieve]
  19. Su, Z., Fan, D., and George, S. E. (1994) J. Biol. Chem. 269, 16761-16765 [Abstract/Free Full Text]
  20. Crivici, A., and Ikura, M. (1995) Annu. Rev. Biophys. Biomol. 24, 85-116 [CrossRef]
  21. DeGrado, W. F., Prendergast, F. G., Wolfe, H. R., and Cox, J. A. (1985) J. Cell. Biochem. 29, 83-93 [Medline] [Order article via Infotrieve]
  22. O'Neil, K. T., Wolfe, H. R., Erickson-Vitanen, S., and DeGrado, W. F. (1987) Science 236, 1454-1456 [Medline] [Order article via Infotrieve]
  23. Fisher, P. J., Prendergast, F. G., Ehrhardt, M. R., Urbauer, J. L., Wand, A. J., Sedarous, S. S., McCormick, D. J., and Buckley, P. J. (1994) Nature 368, 651-653 [Medline] [Order article via Infotrieve]
  24. Montigiani, S., Neri, G., Neri, P., and Neri, D. (1996) J. Mol. Biol. 258, 6-13 [CrossRef][Medline] [Order article via Infotrieve]
  25. Goldberg, J., Nairn, A. C., and Kuriyan, J. (1996) Cell 84, 875-887 [Medline] [Order article via Infotrieve]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.